Join this important trial to reduce the risk of heart failure
The Baker Heart and Diabetes Institute is conducting a trial on the prevention of heart failure for people who have risk factors for developing heart failure.
Who can participate?
You may be eligible for this study if you:
- are aged 65+ years
- have type 2 diabetes.
Enquire about participating in this study
This important drug trial aims to reduce the risk of heart failure for people with type two diabetes. It involves taking a prescription medication daily and attending 5 appointments at our Hoppers Crossing clinic over a 24 month period.
Participants will receive an ultrasound scan of the heart (echocardiogram), a heart trace (electrocardiogram) and blood tests. If selected for the trial, participants will need to take a trial medication daily.
If you would like further information, please contact the Study Coordinators on:
T: (03) 8532 1511
The LEAVE-DM study is a community-based trial that is being conducted by the Baker Heart and Diabetes Institute.
The study aims to determine whether the development of heart failure can be prevented with the use of an anti-diabetic medication called Dapagliflozin. This medication is commonly prescribed in Australia for the treatment of type 2 diabetes and has shown benefit in people with advanced heart failure. We want to know if it can prevent early heart failure from progressing.
Why should I consider participating in this study?
Patient participation will contribute to better prevention of heart failure for people with diabetes.
Participants will receive additional medical attention by being part of the trial, with leading heart specialists. Patients will undergo a full cardiac assessment, including an ultrasound to determine their risk of developing heart failure. There are no costs to participants. All costs for the consultations, medications and tests will be covered by the project.